Covalent or irreversible Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib along with B-cell lymphoma 2 (BCL2) inhibitors, such as venetoclax, block the activity of pathways that are critical for the survival and growth of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) cells. Therefore, on their own, they are highly effective treatments. Still, they are not curative (meaning they don’t completely eliminate all the cancer cells), so many CLL / SLL patients will eventually require additional treatment. Thus far, little is known about how effective treatments are after patients have already been treated with a BTK and/or a BCL2 inhibitor. This study evaluated treatment outcomes in patients with CLL following treatment with these two drug classes using a real-world dataset from the United States.

CLL Society chief medical officer Dr. Brian Koffman discusses results presented at the American Society of Hematology (ASH) 2021 annual meeting.

Read the full article on CLL Society's website at: [ Ссылка ]
__________________________________________________________________________________________
CLL Society Website: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]

свернуть